Israel's MediWound targets $80m IPO
This article was originally published in Clinica
Executive Summary
Israeli wound care specialist MediWound hopes to raise up to $80m in an initial public offering, selling 5 million shares at $14-16 each. The Yavne-based company plans to list on the NASDAQ under the symbol MDWD. Founded in 2001, MediWound is developing products for the management of severe burns and chronic wounds. Its flagship product, NexoBrid, for the removal of burn wound eschar (dead tissue) is approved in Europe for adults with deep partial- and full-thickness thermal burns – MediWound says it is ready to launch there. Fellow Israeli firm Teva Pharmaceutical Industries is an investor in MediWound.